GRIFOLS ADR 1/2/EO-50 (G0F) - Total Liabilities
Based on the latest financial reports, GRIFOLS ADR 1/2/EO-50 (G0F) has total liabilities worth €12.11 Billion EUR (≈ $14.16 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore G0F strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
GRIFOLS ADR 1/2/EO-50 - Total Liabilities Trend (2021–2025)
This chart illustrates how GRIFOLS ADR 1/2/EO-50's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see GRIFOLS ADR 1/2/EO-50 (G0F) total assets.
GRIFOLS ADR 1/2/EO-50 Competitors by Total Liabilities
The table below lists competitors of GRIFOLS ADR 1/2/EO-50 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PEPCO GROUP N.V. EO-01
F:8UX
|
Germany | €2.87 Billion |
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SHG:688266
|
China | CN¥1.86 Billion |
|
Sphere Entertainment Co.
NYSE:SPHR
|
USA | $2.20 Billion |
|
OPENLANE, Inc.
NYSE:OPLN
|
USA | $3.44 Billion |
|
Legence Corp. Class A Common stock
NASDAQ:LGN
|
USA | $2.76 Billion |
|
Zeta Global Holdings Corp
NYSE:ZETA
|
USA | $461.56 Million |
|
Nanning Chemical Industry Co Ltd
SHG:600301
|
China | CN¥2.59 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩388.37 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down GRIFOLS ADR 1/2/EO-50's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See G0F net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GRIFOLS ADR 1/2/EO-50's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GRIFOLS ADR 1/2/EO-50 (2021–2025)
The table below shows the annual total liabilities of GRIFOLS ADR 1/2/EO-50 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €12.11 Billion ≈ $14.16 Billion |
-5.39% |
| 2024-12-31 | €12.80 Billion ≈ $14.96 Billion |
-5.05% |
| 2023-12-31 | €13.48 Billion ≈ $15.76 Billion |
+1.70% |
| 2022-12-31 | €13.25 Billion ≈ $15.49 Billion |
+11.22% |
| 2021-12-31 | €11.92 Billion ≈ $13.93 Billion |
-- |
About GRIFOLS ADR 1/2/EO-50
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more